Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Axsome TherapeuticsAXSM +0.96%52 Debt-to-Equity is 4.03 as of Mar. 2026, which is 284% above its 10-year median of 1.05. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $225.01 (Fairly Valued). The stock has 4 warning signs investors should review. Among 966 Biotechnology companies, Axsome Therapeutics ranks worse than 97.31% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Axsome Therapeutics's Debt-to-Equity or its related term are showing as below:
AXSM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 1.05 Max: 10.4
Current: 4.03
During the past 13 years, the highest Debt-to-Equity Ratio of Axsome Therapeutics was 10.40. The lowest was 0.11. And the median was 1.05.
AXSM's Debt-to-Equity is ranked worse than 97.31% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs AXSM: 4.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Axsome Therapeutics Debt-to-Equity Related Terms
Axsome Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXSM vs MDGL, IONS, BMRN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Axsome Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Axsome Therapeutics (AXSM) has a Debt-to-Equity of 4.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Axsome Therapeutics and its competitors. This is 284% above median its historical median of 1.05. Over the past decade, Axsome Therapeutics' Debt-to-Equity has ranged from 0.11 to 10.40. According to the industry distribution chart, Axsome Therapeutics ranks #940 out of 966 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Axsome Therapeutics' Debt-to-Equity too high?
Axsome Therapeutics' current Debt-to-Equity of 4.03 is 284% above median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 10.40. The Biotechnology industry median Debt-to-Equity is 0.16. Axsome Therapeutics' value of 4.03 is 2418.8% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #940 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' Debt-to-Equity compare to MDGL and IONS?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #940 out of 966 companies for Debt-to-Equity. This places Axsome Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Axsome Therapeutics' value of 4.03 is 2418.8% above this benchmark. Historically, Axsome Therapeutics' own Debt-to-Equity has ranged from 0.11 to 10.40 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 0.16, Axsome Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current Debt-to-Equity of 4.03 is 2418.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current Debt-to-Equity is 4.03, which is 284% above median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $225.01, compared to a current price of $237.53 — trading 5.6% above its estimated fair value. The current Debt-to-Equity is 4.03, which is 284% above median its 10-year median of 1.05 and 2418.8% above the Biotechnology industry median of 0.16. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current Debt-to-Equity is 4.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $237.53 is trading 5.6% above its estimated GF Value™ of $225.01.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for AXSM:
Debt-to-Equity: 4.03 (284% above median its 10-year median of 1.05)
GF Value™: $225.01 vs. price of $237.53 (5.6% above fair value)
Industry Position: 2418.8% above the Biotechnology median (#940 of 966)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 
